Index NDX, S&P 500
P/E 31.61
EPS (ttm) 0.66
Insider Own 17.51%
Shs Outstand 863.67M
Perf Week -0.33%
Market Cap 18.13B
Forward P/E 6.01
EPS next Y 3.50
Insider Trans -0.00%
Shs Float 711.34M
Perf Month -2.82%
Income 574.00M
PEG -
EPS next Q 0.82
Inst Own 59.65%
Short Float 4.38%
Perf Quarter -21.01%
Sales 142.41B
P/S 0.13
EPS this Y -18.70%
Inst Trans -0.06%
Short Ratio 2.31
Perf Half Y -0.52%
Book/sh 22.60
P/B 0.93
EPS next Y 8.07%
ROA 0.60%
Short Interest 31.16M
Perf Year -36.19%
Cash/sh 0.91
P/C 23.12
EPS next 5Y -5.02%
ROE 2.86%
52W Range 19.68 - 36.58
Perf YTD -19.49%
Dividend Est. 1.45 (6.90% )
P/FCF -
EPS past 5Y -
ROI 1.15%
52W High -42.54%
Beta 0.72
Dividend TTM 1.69 (8.04% )
Quick Ratio 0.30
Sales past 5Y 1.35%
Gross Margin 17.21%
52W Low 6.79%
ATR (14) 0.57
Dividend Ex-Date Feb 16, 2024
Current Ratio 0.66
EPS Y/Y TTM 119.40%
Oper. Margin 1.29%
RSI (14) 47.87
Volatility 2.21% 2.59%
Employees 331000
Debt/Eq 1.78
Sales Y/Y TTM 7.73%
Profit Margin 0.40%
Recom 3.10
Target Price 24.88
Option/Short Yes / Yes
LT Debt/Eq 1.57
EPS Q/Q 98.20%
Payout -
Rel Volume 0.92
Prev Close 20.51
Sales Surprise 5.03%
EPS Surprise 7.16%
Sales Q/Q 9.96%
Earnings Mar 28 BMO
Avg Volume 13.50M
Price 21.02
SMA20 0.38%
SMA50 -3.42%
SMA200 -13.51%
Trades
Volume 12,394,434
Change 2.49%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Initiated
Leerink Partners
Market Perform
$23
Feb-20-24 Downgrade
HSBC Securities
Hold → Reduce
Jan-03-24 Initiated
Barclays
Underweight
$21
Dec-22-23 Initiated
HSBC Securities
Hold
$27
Oct-23-23 Upgrade
JP Morgan
Neutral → Overweight
$27 → $30
Jul-03-23 Reiterated
Morgan Stanley
Underweight
$37 → $27
Jun-28-23 Downgrade
Deutsche Bank
Buy → Hold
$46 → $34
Feb-23-23 Initiated
Loop Capital
Buy
$45
Nov-23-22 Resumed
Morgan Stanley
Underweight
$39
Nov-22-22 Upgrade
Cowen
Market Perform → Outperform
$43 → $54
Nov-18-22 Upgrade
JP Morgan
Neutral → Overweight
$42
Nov-11-22 Upgrade
Deutsche Bank
Hold → Buy
Apr-01-22 Downgrade
Robert W. Baird
Outperform → Neutral
$70 → $51
Dec-16-21 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$56 → $49
Mar-25-21 Reiterated
Deutsche Bank
Hold
$49 → $55
Jan-11-21 Upgrade
Robert W. Baird
Neutral → Outperform
$55
Jan-11-21 Upgrade
Guggenheim
Neutral → Buy
$55
Jan-08-21 Resumed
Credit Suisse
Neutral
$42
Apr-06-20 Upgrade
UBS
Sell → Neutral
$49 → $44
Apr-03-20 Upgrade
Deutsche Bank
Sell → Hold
$51 → $43
Show Previous Ratings
Today 08:38AM
08:31AM
08:21AM
08:15AM
07:37AM
07:28AM
Loading…
07:28AM
07:24AM
(The Wall Street Journal)
07:20AM
07:20AM
(The Wall Street Journal)
07:15AM
07:10AM
07:07AM
(Associated Press Finance)
07:07AM
07:00AM
Mar-27-24 05:05PM
04:30PM
Loading…
04:30PM
Mar-26-24 11:18AM
(The Wall Street Journal)
10:35AM
(The Wall Street Journal)
06:05AM
(The Wall Street Journal)
Mar-25-24 12:09PM
11:26AM
(The Wall Street Journal)
09:15AM
Mar-24-24 02:00PM
10:58AM
07:56AM
Mar-23-24 05:43AM
Mar-22-24 05:45PM
04:31PM
07:37AM
Mar-21-24 05:50PM
12:37PM
Loading…
12:37PM
10:00AM
08:30AM
06:16AM
Mar-20-24 01:23PM
08:15AM
Mar-18-24 06:00AM
05:55AM
01:00AM
Mar-15-24 05:45PM
10:05AM
Mar-14-24 01:41PM
09:26AM
09:00AM
Mar-13-24 01:15PM
08:37AM
06:00AM
Mar-12-24 05:50PM
03:31PM
12:15PM
09:26AM
08:30AM
Mar-11-24 07:03PM
05:51PM
05:39PM
12:14PM
Mar-10-24 07:10PM
06:44AM
Mar-09-24 12:14PM
Mar-08-24 12:30PM
11:30AM
03:13AM
Mar-07-24 12:28PM
12:25PM
Mar-06-24 05:45PM
Mar-04-24 11:37AM
11:10AM
10:00AM
09:51AM
09:42AM
09:30AM
08:26AM
03:58AM
Mar-01-24 04:27PM
01:28PM
(Associated Press Finance)
01:09PM
(The Wall Street Journal)
11:40AM
11:36AM
11:27AM
11:12AM
03:48AM
Feb-29-24 10:05PM
(Thomson Reuters StreetEvents)
07:41PM
(Investor's Business Daily)
05:45PM
11:15AM
09:19AM
Feb-28-24 09:00AM
Feb-27-24 06:48PM
05:50PM
11:27AM
Feb-26-24 04:05PM
11:41AM
(The Wall Street Journal)
10:59AM
09:57AM
(The Wall Street Journal)
09:45AM
(The Wall Street Journal)
09:33AM
08:30AM
Feb-24-24 07:55AM
Feb-23-24 05:21AM
01:59AM
Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walgreens Boots Alliance, Inc. 10% Owner Feb 07 '24 Sale 235.41 4,212,395 991,639,907 26,277,561 Feb 09 07:00 AM JARRETT VALERIE B Director Jan 29 '24 Buy 22.44 4,456 99,993 4,456 Jan 31 04:11 PM SCHLICHTING NANCY M Director Jan 16 '24 Sale 23.05 15,209 350,567 0 Jan 18 04:18 PM WENTWORTH TIMOTHY C Chief Executive Officer Jan 05 '24 Buy 24.22 10,000 242,220 585,122 Jan 08 07:29 AM Gates Richard P. SVP, Chief Pharmacy Officer Nov 10 '23 Sale 20.45 1,000 20,450 73,929 Nov 14 08:22 PM Walgreens Boots Alliance, Inc. 10% Owner Nov 09 '23 Sale 195.38 1,279,590 249,999,896 30,489,956 Nov 14 07:15 AM Walgreens Boots Alliance, Inc. 10% Owner Aug 03 '23 Sale 189.27 1,320,858 250,000,115 31,769,546 Aug 07 05:48 PM DRISCOLL JOHN PATRICK EVP, Pres. U.S. Healthcare Jun 30 '23 Buy 28.42 5,172 146,984 59,050 Jul 05 06:57 PM Walgreens Boots Alliance, Inc. 10% Owner Jun 15 '23 Sale 181.17 275,984 50,000,021 33,090,404 Jun 20 06:03 AM Walgreens Boots Alliance, Inc. 10% Owner May 11 '23 Sale 170.77 292,792 50,000,090 33,366,388 May 15 05:18 PM BREWER ROSALIND G CEO Mar 29 '23 Buy 33.95 10,000 339,510 369,945 Mar 31 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite